高级别骨肉瘤治疗后骨微结构与骨折关联的对照研究
本研究对19例20多年前接受化疗的骨肉瘤患者进行随访,采用双能X线吸收法测骨密度、问卷评估骨折史,并用高分辨率外周定量CT比较骨微结构。结果发现患者骨量减少或骨质疏松常见,骨折比例高于对照,但仅骨内膜周长增加,其他微结构参数无差异。
要点
- 骨肉瘤化疗后长期生存者骨量减少或骨质疏松常见,骨折风险高于对照。
- 高分辨率外周定量CT未发现骨微结构参数(除骨内膜周长外)与对照有差异。
- 建议定期监测骨密度,低骨密度者考虑骨质疏松治疗。
核心结论
- 骨肉瘤治疗后患者骨密度降低且骨折比例更高,但骨微结构参数未见明确差异,骨折增加可能并非由骨几何或微结构改变所致。
研究设计与样本
- 对48例20多年前接受多模式治疗(含化疗)的骨肉瘤患者中19例(男9例、女10例,平均年龄46±4岁,术后平均28±3年)进行对照研究,对照为年龄性别匹配、骨密度正常(脊柱和髋部T值>-1.0)的499例健康成人队列样本。
主要发现
- 骨肉瘤患者报告骨折11/19例,对照组2/19例(p<0.001)。
- 仅骨内膜周长在患者组增加(75±15 mm vs 62±18 mm;p=0.04),皮质骨和松质骨面积、厚度及皮质孔隙率无差异。
关键数值与推荐
- 骨密度用双能X线吸收法测量,骨折史用问卷评估,微结构用高分辨率外周定量CT评估。
- 组间连续变量用Wilcoxon秩和检验,分类变量用卡方检验,并进行多元回归分析。
临床怎么用
- 对骨肉瘤化疗后长期生存者应定期进行骨密度检测。
- 对低骨密度患者应考虑骨质疏松治疗。
局限性
- 样本量小(仅19例患者),且原队列中60%失访。
- 对照组的骨密度正常可能引入选择偏倚。
- 横断面设计无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy in patients with primary osteosarcoma improves survival rates, but it also causes side effects in various organs including bone. Low bone mineral density (BMD) can occur owing partly to chemotherapy or limited mobility. This can cause a higher risk of fractures compared with those who do not receive such treatment. Changes in BMD alone cannot explain the propensity of fractures. Studying microarchitectural changes of bone might help to understand the effect. QUESTIONS/PURPOSES: (1) Do patients who were treated for osteosarcoma (more than 20 years previously) have low BMD? (2) Do these patients experience more fractures than controls who do not have osteosarcoma? (3) What differences in bone microarchitecture are present between patients treated for high-grade osteosarcoma and individuals who have never had osteosarcoma? METHODS: We contacted 48 patients who were treated for osteosarcoma and who participated in an earlier study. These patients underwent multimodal treatment including chemotherapy more than 20 years ago. Of the original patient group, 60% (29 of 48) were missing, leaving 40% (19 of 48) available for inclusion in this study; all 19 agreed to participate. There were nine men and 10 women with a mean age of 46 ± 4 years and a mean time from surgery to examination of 28 ± 3 years. BMD was measured by dual-energy x-ray absorptiometry, and any fracture history was assessed using a questionnaire. Additionally, high-resolution peripheral quantitative CT was performed to compare the groups in terms of microarchitectural changes, such as cortical and trabecular area, cortical and trabecular thickness, cortical porosity, and endocortical perimeter. Participants in the control group were selected from a cohort consisting of a population-based random sample of 499 healthy adult women and men. Osteoporosis or low BMD was not an exclusion criterion for entering this study; however, the patients in the control group were selected based on a normal BMD (that is, T score > -1.0 at both the spine and hip). Also, the participants were matched based on age and sex. Differences between patients and controls were assessed using the Wilcoxon rank sum test for continuous variables and a chi-square test for categorical variables. A multiple regression analysis was performed. Model assumptions were checked using histograms and quantile-quantile plots of residuals. RESULTS: Twelve of 19 patients who were treated for osteosarcoma had either osteopenia (eight patients) or osteoporosis (four patients). More patients with osteosarcoma reported sustaining fractures (11 of 19 patients) than did control patients (2 of 19 controls; p < 0.001). Among all microarchitectural parameters, only the endocortical perimeter was increased in patients compared with the control group (75 ± 15 mm versus 62 ± 18 mm; p = 0.04); we found no differences between the groups in terms of cortical and trabecular area, cortical and trabecular thickness, or cortical porosity. CONCLUSION: Although patients who were treated for osteosarcoma had osteopenic or osteoporotic BMD and a higher proportion of patients experienced fractures than did patients in the control group, we could not confirm differences in microarchitectural parameters using high-resolution peripheral quantitative CT. Therefore, it seems that bone geometry and microstructural parameters are not likely the cause of the increased proportion of fractures observed in our patients who were treated for osteosarcoma. Until we learn more about the bone changes associated with chemotherapy in patients with osteosarcoma, we recommend that patients undergo regular BMD testing, and we recommend that physicians consider osteoporosis treatment in patients with low BMD. These data might provide the impetus for future multicenter prospective studies examining the association between chemotherapy and bone microarchitecture. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Holzer G, Hobusch G, Hansen S, et al. Is There an Association Between Bone Microarchitecture and Fracture in Patients who were Treated for High-grade Osteosarcoma? A Controlled Study at Long-term Follow-up Using High-resolution Peripheral Quantitative CT. Clin Orthop Relat Res. 2021. PMID: 34077400. doi:10.1097/CORR.0000000000001842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。